Jakubowitz Law IS HERE TO HELP SHAREHOLDERS WHO PURCHASED Reata Pharmaceuticals, Inc. (RETA)

(i) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of FA in the U.S. without additional evidence; (ii) as a result, it was foreseeable that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you incurred a loss on RETA stocks purchased between October 15, 2019 and August 7, 2020, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the Eastern District of Texas, and our firm is reaching out to investors to discuss their legal rights.

If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.

You only have until December 14, 2020 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.

Enter the following information for this class action case- the deadline is approaching.